Streetwise Reports' Article Archives — January 2012 back to current month (2)
Hepatitis C and Orphan Diseases Driving Big Biotech Potential: Geoff Meacham (01/31/2012)
It may seem counterintuitive that rare diseases might actually be biotech growth drivers, but Senior Analyst and Managing Director Geoff Meacham of JPMorgan Chase makes just that case. In this exclusive interview with The Life Sciences Report, Meacham lays out his premise that hepatitis C and orphan disease drugs can cure the woes of growth-starved investors.
Driving Value for Pharma and Biotech Companies: Insights from Biotech Showcase 2012 (01/20/2012)
The 2012 Biotech Showcase investor conference in San Francisco drew a record number of life science interests from all over the world.
More Archives
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec